Skip to Content

Roche Holding AG ROG

Morningstar Rating
CHF 248.90 +1.00 (0.40%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Roche's Pharma Pipeline and Diagnostics Innovation Support a Wide Moat

We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare giant is in a unique position to guide global health care into a safer, more personalized, and more cost-effective endeavor. Strong information sharing continues between Genentech and Roche researchers, boosting research and development productivity and personalized medicine offerings that take advantage of Roche's diagnostic expertise.

Price vs Fair Value

ROG is trading at a 84% premium.
Price
CHF 247.90
Fair Value
CHF 795.00
Uncertainty
Low
1-Star Price
CHF 843.23
5-Star Price
CHF 411.10
Economic Moat
Ssgcp
Capital Allocation
Kylblbdky

Bulls Say, Bears Say

Bulls

Roche and its innovative U.S. arm Genentech have a solid history of generating blockbuster therapies in oncology, and Roche's pipeline is full of novel candidates, with a particularly large late-stage pipeline.

Bears

Roche's immuno-oncology drug Tecentriq was launched third to market behind Bristol's Opdivo and Merck's Keytruda, raising questions about Roche's innovation.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ROG is a good fit for your portfolio.

News

Trading Information

Previous Close Price
CHF 247.90
Day Range
CHF 247.80249.40
52-Week Range
CHF 212.90279.85
Bid/Ask
CHF 248.80 / CHF 248.90
Market Cap
CHF 198.43 Bil
Volume/Avg
357,437 / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
12.66
Price/Sales
3.30
Dividend Yield (Trailing)
3.87%
Dividend Yield (Forward)
3.87%
Total Yield
3.87%

Company Profile

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
103,605

Competitors

Valuation

Metric
ROG
MRK
ABBV
Price/Earnings (Normalized)
12.6658.9815.64
Price/Book Value
6.748.0337.79
Price/Sales
3.305.315.58
Price/Cash Flow
12.1318.6616.15
Price/Earnings
ROG
MRK
ABBV

Financial Strength

Metric
ROG
MRK
ABBV
Quick Ratio
0.990.680.72
Current Ratio
1.351.250.94
Interest Coverage
14.933.973.95
Quick Ratio
ROG
MRK
ABBV

Profitability

Metric
ROG
MRK
ABBV
Return on Assets (Normalized)
17.03%5.22%14.14%
Return on Equity (Normalized)
53.42%13.56%172.29%
Return on Invested Capital (Normalized)
26.30%8.29%27.87%
Return on Assets
ROG
MRK
ABBV
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
NmmtdpvfndBrpg$847.2 Bil
Johnson & Johnson
JNJ
QkccmybGry$350.5 Bil
Merck & Co Inc
MRK
FntztfzCzsk$324.2 Bil
AbbVie Inc
ABBV
FcyfzqccWkpx$302.6 Bil
AstraZeneca PLC ADR
AZN
XcmrpxkgZmjy$244.7 Bil
Roche Holding AG ADR
RHHBY
BgbvrfnyVfsb$225.7 Bil
Novartis AG ADR
NVS
VztljbkcDkjg$213.9 Bil
Amgen Inc
AMGN
KtxfkcryrnRkts$164.1 Bil
Pfizer Inc
PFE
NdlxvlvgMqb$155.3 Bil
Sanofi SA ADR
SNY
MwzvktdMjkrw$118.9 Bil

Sponsor Center